http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
-
Guardant Health gets FDA approval for breast cancer diagnostic test
-
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mu
-
Guardant Health partners with Nuvalent for cancer diagnostics development
-
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infi
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
-
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
-
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
-
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
-
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
-
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
-
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
-
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
-
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health blood test shows improved cancer recurrence prediction
-
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Trea
-
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
-
Guardant Health gets FDA approval for colorectal cancer test
-
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
-
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
-
Guardant Health posts 39% revenue growth in fourth quarter
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
-
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
-
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
-
Guardant Health launches liquid biopsy testing at Italian hospital
-
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
-
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San A
-
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
-
Guardant Health expands blood test for late-stage cancer monitoring
-
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
-
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
-
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
Guardant Health partners with Zephyr AI for cancer biomarker research
-
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
-
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
-
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
-
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
-
FDA approves Guardant Health test for Eli Lilly breast cancer drug
-
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
-
Guardant Health partners with Quest for blood-based cancer screening
-
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
-
Former health secretary Alex Azar joins Guardant Health board
